A new federally funded study published in the Journal of Affective Disorders found that medical marijuana significantly decreased self-reported anxiety and depression in patients within three months of initiation, with sustained reductions over six months. The study, conducted by Johns Hopkins University and funded in part by NIDA, observed 33 adults in Maryland who used medical cannabis. Most participants chose THC-dominant products, and while reporting mental health benefits, also noted a decline in perceived driving ability and an increase in feeling high. Authors recommend further controlled clinical trials to investigate efficacy and safety. Other recent research also supports cannabis, particularly CBD, for its potential antidepressant and anti-anxiety properties.

Federally Funded Study Shows Medical Cannabis Helps Reduce Anxiety and Depression

Jul 10, 2025

Source:

Ben Adlin

Marijuana Moment

It’s always a win when science finally catches up to what the community has known for years. A new study out of Johns Hopkins—partially funded by the feds, no less—shows that medical cannabis is a powerhouse for tackling anxiety and depression. Researchers followed patients in Maryland and found that those using THC-heavy products saw their symptoms plummet within just three months. The sweet spot for relief seemed to be around 10 to 15mg of edibles or at least three puffs from a vape.

While participants noted they felt less sharp behind the wheel, the mental health trade-off was huge, with many seeing their distress levels drop below clinical thresholds for the long haul. This is a massive deal for regular tokers because it adds serious weight to the argument for cannabis as a legitimate alternative to traditional pharmaceuticals. It’s not just about the buzz; it’s about finding a natural path to peace of mind. For a community often fighting stigma, this data is the ultimate validation that plant medicine belongs in the mainstream.